News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why Valeant (VRX) Can't "Dig Out Of That Hole" Fast Enough



11/9/2016 7:28:12 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The shares are plunging.

Scheduling its earnings report on Election Day was already a signal that Valeant Pharmaceuticals didn’t have great news to share.

But the troubled drug company managed to disappoint investors anyway. Valeant stock plunged 22% as the drugmaker slashed its guidance for the rest of 2016, even with less than two months left in the year.

It’s the second time this year that Valeant has had to cut its earnings forecast. Last time it did so, in March, Valeant’s stock lost half of its value in a day. Valeant shares are down 85% this year, and 95% since their peak price in summer 2015, as accounting errors have led to a criminal investigation of its practices and its drug-price increases have come under fire with regulators.

Read at Fortune


comments powered by Disqus
Fortune
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES